Related Experiment Video
Updated: Jan 11, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Current evidence and future directions in antiplatelet therapy for spontaneous coronary artery dissection: balancing
Mucahit Yetim1, Abdülmelik Birgün2, Abdullah Sarihan1
1Depertament of Cardiology, Faculty of Medicine, Hitit University.
Insights
Antiplatelet therapy for spontaneous coronary artery dissection (SCAD) lacks direct evidence, leading to uncertain clinical practice. More research is urgently needed to determine optimal antiplatelet strategies for SCAD patients.
Area of Science:
- Cardiology
- Vascular Medicine
Background:
- Spontaneous coronary artery dissection (SCAD) is an emerging cause of acute coronary syndromes (ACS), especially in young women.
- Conservative management is preferred for stable SCAD patients, but antiplatelet therapy's role is unclear.
- Current practices extrapolate from ACS guidelines, lacking specific evidence for SCAD.
Purpose of the Study:
- To review the literature on antiplatelet therapy after conservative SCAD management.
- To examine mechanistic rationale, guidelines, registry data, and clinical approaches.
- To highlight evidence limitations and the need for randomized trials.
Main Methods:
- Literature review of antiplatelet therapy in SCAD.
- Analysis of mechanistic rationale and guideline recommendations.
- Evaluation of observational registry data.
Main Results:
- Conflicting results exist regarding antiplatelet therapy benefits and risks in SCAD.
- Some studies suggest reduced recurrent ischemic events, while others note increased bleeding or hematoma propagation.
- Evidence for optimal antiplatelet strategy in SCAD is limited.
Conclusions:
- Antiplatelet therapy in SCAD requires individualized approaches.
- Current evidence is insufficient to guide definitive treatment.
- Randomized controlled trials are essential to establish optimal antiplatelet strategies for SCAD.
Abstract:
Spontaneous coronary artery dissection (SCAD) has emerged as an increasingly recognized cause of acute coronary syndromes (ACSs), particularly in young women without traditional atherosclerotic risk factors. While conservative management has become the preferred strategy in most stable patients, the role of antiplatelet therapy in this unique setting remains uncertain. Current clinical practice often extrapolates from ACS guidelines, recommending aspirin monotherapy or dual antiplatelet therapy, despite a paucity of direct evidence. Observational registries have provided conflicting results, with some suggesting a benefit of antiplatelet therapy in reducing recurrent ischemic events, whereas others highlight the potential risks of intramural hematoma propagation and bleeding. This review aims to critically examine the available literature on antiplatelet therapy following conservatively managed SCAD, highlighting mechanistic rationale, guideline perspectives, registry data, and evolving clinical approaches. The discussion emphasizes the need for individualized therapy, the limitations of current evidence, and the urgent requirement for randomized controlled trials to establish optimal antiplatelet strategies in this unique population.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Acute Coronary Syndrome IV: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

